Never miss a story

Get subscribed to our newsletter


×
US are studying the effectiveness of an arthritis drug in treating a type of severe immune overreaction in patients with Covid-19 induced pneumonia in a Phase 3 clinical trial. Pixabay

Researchers at The University of Texas Health Science Center at Houston (UTHealth) in the US are studying the effectiveness of an arthritis drug in treating a type of severe immune overreaction seen in patients with Covid-19 induced pneumonia in a Phase 3 clinical trial.

The clinical trial is enrolling patients at the Harris Health System’s Lyndon B. Johnson Hospital in Houston, Texas.


The Phase 3 study is evaluating the effectiveness of the drug canakinumab, an interleukin-1 (IL-1) blocker approved for the treatment of juvenile rheumatoid arthritis, for preventing cytokine release syndrome (CRS) in Covid-19 patients with pneumonia.

Follow NewsGram on Quora Space to get answers to all your questions.

Often referred to as a cytokine storm, CRS is a life-threatening immune reaction caused by the body releasing too many cytokines into the blood at once.

Cytokines include a broad category of proteins secreted by the body.


Cytokines include a broad category of proteins secreted by the body. Pixabay

Interleukin-1 serves as the first-line defence for the immune system, alerting other proteins to respond if a virus or bacteria are present.

Canakinumab blocks the production of IL-1 protein, which could prevent a possible deadly overreaction of the immune system in Covid-19 patients.

Research has linked a number of Covid-19 deaths to CRS due to damage caused to several major organs.

Roberto C. Arduino, MD, the study’s lead investigator and professor of infectious disease at the McGovern Medical School in UTHealth, said this is a time for the HIV research community to utilise the members’ expertise in the search for a treatment for coronavirus.

Arduino’s research background includes the study of new antiretroviral drugs, treatment strategies, immune activation, and inflammation in the search of an HIV cure.

“The research community truly feels compelled to do something in the search for a viable treatment for Covid-19, and I feel I owe it to my community to offer my expertise,” said Arduino, who has led HIV clinical research for 22 years.


Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight. Pixabay

Also Read: Stay Acne Proof This Monsoon Season

Researchers are investigating if canakinumab combined with standard-of-care treatment can increase the chances of survival without ever requiring invasive mechanical ventilation in patients with Covid-19-induced pneumonia.

Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight, UTHealth said in a statement on Monday. Arduino is the study’s lead investigator.

All participants will be monitored for up to 29 days, or until they are discharged from the hospital. A follow-up will occur at 127 days. (IANS)


Popular

Photo by luis arias on Unsplash

Exclusive feeding for over a year as per the doctor's advice remains key for your baby to stay healthy and keep various allergies, infections, and diseases away.

By Peeyoosh Rankhamb

Parents, do you have any doubts regarding what to feed your newborn during the first year? Are you becoming anxious because of this? What should be the eating schedule for your baby?

The right kind of nutrition during the early years of life can help in the growth and development of the little one. Thus, exclusive feeding for over a year as per the doctor's advice remains key for your baby to stay healthy and keep various allergies, infections, and diseases away. Breastfeeding is vital for the baby and fulfils the baby's requirement of nutrition. At six months you need to also introduce the baby to solid foods.

Here's a list of do's and don'ts that you need to follow

* Do not introduce your baby to solid foods immediately after the first few months. The little one may not be ready for it and you will have a tough time making the baby eat this food. You should give breast milk to your child and formula milk can be given after consulting the doctor. Just be patient and follow the suggestions given by the expert.

Baby feeding from a bottle You should give breast milk to your child and formula milk can be given after consulting the doctor. | Photo by Lucy Wolski on Unsplash

Keep Reading Show less
Pixabay

Samsung Electronics, the world's number two foundry firm behind Taiwan's TSMC, announced in May that it will build a $17 billion fab in the US.

Samsung Electronics will quickly decide on a foundry investment in the US, a senior executive said Tuesday, as the South Korean tech giant seeks to become the world's number one player in the logic chip and foundry sectors. Samsung Electronics, the world's number two foundry firm behind Taiwan's TSMC, announced in May that it will build a $17 billion fab in the US.

Samsung's de facto leader Lee Jae-yong is widely speculated to visit the US, possibly next month, to finalise the site, with the city of Taylor, Texas, emerging as the strongest candidate. Other candidates include Arizona, New York, and Austin, Texas. Kim Ki-nam, Vice Chairman and CEO of Samsung's device solutions division, said it takes time for the company to review all the factors such as "infrastructure, site, personnel and state incentives," and make a final decision.

"We are trying to make a decision as soon as possible," Kim told reporters on the sidelines of the Korea Electronics Show 2021, which is under way at an exhibition center in southern Seoul. He made the comments when asked whether Samsung will make an investment within this year. He did not elaborate, reports Yonhap news agency.

Separately, Kim said the company has been "calmly" preparing answers to a recent request by the US Department of Commerce about its semiconductor business. The US has asked global chipmakers, including Samsung, to share information on inventories and demanded other details by November 8 to "help improve trust and transparency within the supply chain." The request spawned concerns about the leak of chipmakers' major trade secrets. (IANS/ MBI)


Keep Reading Show less
Wikimedia Commons

'Vikram Vedha' is a Hindi remake of the runaway Tamil hit of the same name which was released in 2017.

It's been over two years since Hrithik Roshan appeared on celluloid. Fans have been waiting to witness his next performance on the silver screen and it seems like their wishes will be soon granted. Earlier, Hrithik had made an announcement about getting back to shooting schedule for the upcoming film 'Vikram Vedha'. And now, it's learnt that the actor has recently wrapped the first ever action sequence from the film.

The news came out when a few stuntmen from the film's set shared pictures of the sequence wrap. The stunt sequences seem to be quite crazy as suggested by the stuntmen. Talking about the same, a stuntman posted on his instagram as he wrote, "Wrapped up the first action sequence of Vikram Vedha. A big 'Thank you' to @parvez.shaikhh sir for this opportunity. Wouldn't have been possible without you ?? @hrithikroshan."

Another stuntman posted, "First craziest action sequence have done (sic).!! Cheer's To @hrithikroshan @parvez.shaikhh @stuntindia1 and all the stunt boys.!!"

'Vikram Vedha' is a Hindi remake of the runaway Tamil hit of the same name which was released in 2017. While the original action thriller starred R. Madhavan and Vijay Sethupathi, the Hindi version will see Hrithik Roshan squaring off against Saif Ali Khan. (IANS/ MBI)


Keep reading... Show less